1
|
Brett T, Marquina C, Radford J, Heal C, Hespe C, Gill G, Sullivan D, Zomer E, Morton J, Watts G, Pang J, Ademi Z. Enhancing the potential for increased primary care role in familial hypercholesterolaemia detection and management: Cost-effectiveness and return on investment. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
2
|
Brett T, Radford J, Heal C, Gill G, Hespe C, Sullivan D. An approach to detection and management of familial hypercholesterolaemia (FH) in Australian general practice – A pragmatic, multicentre study in 15 research practices. Atherosclerosis 2021. [DOI: 10.1016/j.atherosclerosis.2021.06.538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Ghione P, Ghesquieres H, Bobillo S, Patel AR, Kanters S, Deighton K, Dong H, Yang Y, Ma L, Limbrick‐Oldfield EH, Thornton Snider J, Wade SW, Riberio MT, Sudhindra A, Radford J, Palomba ML, Gribben J. OUTCOMES IN LATER‐LINES OF THERAPY FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE INTERNATIONAL SCHOLAR‐5 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.26_2880] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Ghione
- Roswell Park Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center Buffalo and New York New York USA
| | - H. Ghesquieres
- Hospices Civils de Lyon Centre Hospitalier Lyon Sud Lyon France
| | - S. Bobillo
- Vall D’Hebron Insitute of Oncology Department of Haematology and Oncology Barcelona Spain
| | | | | | | | - H. Dong
- RainCity Analytics Vancouver Canada
| | - Y. Yang
- Kite, A Gilead Company Santa Monica USA
| | - L. Ma
- Kite, A Gilead Company Santa Monica USA
| | | | | | - S. W. Wade
- Wade Outcomes Research and Consulting Salt Lake City, Utah USA
| | - M. T. Riberio
- Portuguese Oncology Institute of Porto Porto Portugal
| | | | - J. Radford
- The Christie NHS Foundation Trust and University of Manchester Manchester UK
| | - M. L. Palomba
- Memorial Sloan Kettering Cancer Center, New York New York USA
| | - J. Gribben
- Cancer Research UK Barts Centre London UK
| |
Collapse
|
4
|
Zinzani PL, Caimi PF, Carlo‐Stella C, Ai W, Alderuccio JP, Ardeshna KM, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Feingold J, Ungar D, Qin Y, He S, Hamadani M. LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.89_2880] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- P. L. Zinzani
- IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia "Seràgnoli" and Diagnostica e Sperimentale Università di Bologna Dipartimento di Medicina Specialistica Bologna Italy
| | - P. F. Caimi
- Case Western Reserve University University Hospitals Cleveland Medical Center Cleveland USA
| | - C. Carlo‐Stella
- Humanitas Clinical and Research Center – IRCCS, and Humanitas University Department of Oncology and Hematology Rozzano Milan Italy
| | - W. Ai
- University of California Division of Hematology and Oncology Department of Medicine San Francisco USA
| | - J. P. Alderuccio
- University of Miami Sylvester Comprehensive Cancer Center Miami USA
| | - K. M. Ardeshna
- University College London Hospitals NHS Foundation Trust Department of Haematology London UK
| | - B. Hess
- Medical University of South Carolina Division of Hematology and Medical Oncology Department of Medicine Charleston USA
| | - B. S. Kahl
- Washington University Department of Medicine Oncology Division St Louis USA
| | - J. Radford
- Christie NHS Foundation Trust and the University of Manchester NIHR Clinical Research Facility Manchester UK
| | - M. Solh
- Northside Hospital Blood and Marrow Transplant Program AtlantaGeorgia USA
| | - A. Stathis
- Oncology Institute of Southern Switzerland Division of Medical Oncology Bellinzona Switzerland
| | - J. Feingold
- ADC Therapeutics America, Inc Clinical Development Murray Hill USA
| | - D. Ungar
- ADC Therapeutics America, Inc Clinical Development Murray Hill USA
| | - Y. Qin
- ADC Therapeutics America, Inc Clinical Development Murray Hill USA
| | - S. He
- ADC Therapeutics America, Inc Clinical Development Murray Hill USA
| | - M. Hamadani
- Medical College of Wisconsin Division of Hematology and Oncology Milwaukee USA
| |
Collapse
|
5
|
Zinzani PL, Carlo‐Stella C, Hamadani M, Herrera AF, Ansell SM, Radford J, Maddocks K, Kline J, Savage KJ, Bartlett NL, Caimi PF, Negievich Y, Cruz HG, Wang L, Wuerthner J, Collins GP. CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL). Hematol Oncol 2021. [DOI: 10.1002/hon.75_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. L. Zinzani
- IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia "Seràgnoli" and Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Università di Bologna Bologna Italy
| | - C. Carlo‐Stella
- Humanitas Clinical and Research Center – IRCCS, and Humanitas University Department of Oncology and Hematology Rozzano Milan Italy
| | - M. Hamadani
- Medical College of Wisconsin BMT & Cellular Therapy Program Department of Medicine Milwaukee Wisconsin USA
| | - A. F. Herrera
- City of Hope Comprehensive Cancer Center Department of Hematology & Hematopoietic Cell Transplantation Duarte California USA
| | - S. M. Ansell
- Mayo Clinic Division of Hematology Rochester Minnesota USA
| | - J. Radford
- NIHR Manchester Clinical Research Facility The Christie NHS Foundation Trust and University of Manchester Manchester Academic Health Science Centre Manchester UK
| | - K. Maddocks
- Ohio State University Medical Center Division of Hematology Columbus Ohio USA
| | - J. Kline
- The University of Chicago Department of Medicine Chicago Illinois USA
| | - K. J. Savage
- BC Cancer and University of British Columbia Department of Medical Oncology Vancouver BC Canada
| | - N. L. Bartlett
- Washington University School of Medicine in St Louis Division of Oncology St Louis Montana USA
| | - P. F. Caimi
- University Hospitals Cleveland Medical Center/Case Western Reserve University Department of Medicine Cleveland Ohio USA
| | - Y. Negievich
- ADC Therapeutics SA Clinical Development Epalinges Switzerland
| | - H. G. Cruz
- ADC Therapeutics SA Clinical Development Epalinges Switzerland
| | - L. Wang
- ADC Therapeutics America, Inc, Clinical Development Murray Hill New Jersey USA
| | - J. Wuerthner
- ADC Therapeutics SA Clinical Development Epalinges Switzerland
| | - G. P. Collins
- Churchill Hospital NIHR Oxford Biomedical Research Centre Oxford Cancer and Haematology Centre Oxford UK
| |
Collapse
|
6
|
Aurer I, Neven A, Fiaccadori V, Counsell N, Phillips E, Clifton‐Hadley L, Fortpied C, Andre M, Federico M, Barrington S, Illidge T, Radford J, Raemaekers J. RELAPSES IN INTERIM PET NEGATIVE LIMITED STAGE HODGKIN LYMPHOMA PATIENTS RECEIVING ABVD WITH OR WITHOUT RADIOTHERAPY–ANALYSIS OF EORTC/FIL/LYSA H10 AND UK NCRI RAPID TRIALS. Hematol Oncol 2021. [DOI: 10.1002/hon.71_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- I. Aurer
- University Hospital Centre Zagreb Division of Hematology Department of Internal Medicine Zagreb Croatia
| | - A. Neven
- European Organisation for Research and Treatment of Cancer Lymphoma Group Brussels Belgium
| | - V. Fiaccadori
- University College London Cancer Institute London UK
| | - N. Counsell
- University College London Cancer Research UK and University College London Cancer Trials Centre London UK
| | - E. Phillips
- University of Manchester The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - L. Clifton‐Hadley
- University College London Cancer Research UK and University College London Cancer Trials Centre London UK
| | - C. Fortpied
- European Organisation for Research and Treatment of Cancer Lymphoma Group Brussels Belgium
| | - M. Andre
- Université Catholique de Louvain Department of Hematology Yvoir Belgium
| | - M. Federico
- University of Modena and Reggio Emilia CHIMOMO Department Modena Italy
| | - S. Barrington
- King's College London King's College London and Guy's and St Thomas' PET Centre London UK
| | - T. Illidge
- University of Manchester The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - J. Radford
- University of Manchester The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - J. Raemaekers
- Radboud University Medical Centre Department of Hematology Nijmegen Netherlands
| |
Collapse
|
7
|
Phillips EH, Counsell N, Illidge T, Andre M, Aurer I, Fiaccadori V, Fortpied C, Neven A, Federico M, Clifton‐Hadley L, Barrington S, Raemaekers J, Radford J. BASELINE MAXIMUM TUMOUR DIAMETER IS ASSOCIATED WITH EVENT‐FREE SURVIVAL FOR PET‐NEGATIVE PATIENTS WITH LIMITED‐STAGE HODGKIN LYMPHOMA: ANALYSIS OF THE H10 AND RAPID TRIALS. Hematol Oncol 2021. [DOI: 10.1002/hon.115_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- E. H. Phillips
- University of Manchester, The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - N. Counsell
- University College London, Cancer Research UK and UCL Cancer Trials Centre London UK
| | - T. Illidge
- University of Manchester, The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - M. Andre
- CHU UCL Namur, Department of Haematology Yvoir Belgium
| | - I. Aurer
- University Hospital Centre Zagreb, Division of Hematology, Department of Internal Medicine Zagreb Croatia
| | - V. Fiaccadori
- University College London, Cancer Institute London UK
| | - C. Fortpied
- European Organisation for Research and Treatment of Cancer, EORTC Headquarters Brussels Belgium
| | - A. Neven
- European Organisation for Research and Treatment of Cancer, EORTC Headquarters Brussels Belgium
| | - M. Federico
- University of Modena and Reggio Emilia, CHIMOMO Department Modena Italy
| | - L. Clifton‐Hadley
- University College London, Cancer Research UK and UCL Cancer Trials Centre London UK
| | - S. Barrington
- King's College London and King's Health Partners, King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences London UK
| | - J. Raemaekers
- Radboud University Medical Center, Department of Haematology Nijmegen Netherlands
| | - J. Radford
- University of Manchester, The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| |
Collapse
|
8
|
Piddock K, Britton F, Goode V, White E, Greenstein A, Linton KM, Radford J. P6238International cardiovascular disease risk calculators do not identify high risk in young hodgkin lymphoma survivors. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Cardiotoxic therapy causes significant morbidity and mortality in patients (pts) treated for Hodgkin lymphoma (HL). Cardiovascular (CVS) risk calculators do not include cancer therapy despite epidemiological data demonstrating increased risk. We have assessed modifiable CVS risk factors and predicted risk of CVS disease in a cohort of HL survivors.
Hypothesis
Cardiovascular risk calculators will not identify high risk in young HL survivors.
Methods
Pts now aged ≤50 treated with doxorubicin and/or radiotherapy (RT) to cardiac tissue for HL >5 years ago were identified. Telephone review of CVS risk factors was offered to pts taking statins or already diagnosed with cerebrovascular or CVS disease. Remaining pts were offered clinical review to assess BMI, blood pressure, cholesterol and HbA1c. Carotid-radial pulse wave velocity (PWV) was measured if available. CVS risk was predicted using international risk calculators (European SCORE, QRISK3, Framingham).
Results
160 eligible pts were identified. Median age was 43 years (26–50) and 52% were female. Median time since treatment was 182 months (61–367). Pts received doxorubicin (n=150), with RT (n=97) or RT alone (n=10). Pts were excluded from study due to severe medical condition (n=8), recurrence (n=1), relocation (n=3) or death (n=1). Data were gathered at clinical review (n=70) or telephone review (n=26). Existing cardiovascular diagnoses included hypertension (n=5), transient ischaemic attack (n=2), valvular disease (n=3), heart failure (n=1), atrial fibrillation (n=2), complete heart block (n=1) and coronary artery disease (n=1).
At clinical review 51% pts had 3 or more modifiable risk factors with a median of 3 (0–5) per pt. Total cholesterol was >5.0 mmol/L in 58% of patients with a median of 5.2 mmol/L (3.2–8.6). Median systolic blood pressure was 125.5 mmHg (103–164). Median body mass index was 26.3 kg/m-2 (18.6–56.1) with 60% of patients classed as overweight or obese.Advice was offered to all smokers (9%), pts that drank alcohol above UK recommended levels (20%) or exercised below the recommended amount (60%). Risk calculators classified 1.4% (QRISK3) and 10% (Framingham) of pts at high risk of CVS disease and 0% (European SCORE) at high risk of CVS mortality. Pulse wave velocity measured in 34 pts was elevated (>8 m/s) in 76% of cases with a median 10.2 m/s (2.3–16.8).
Conclusions
Numerous modifiable CVS risk factors were identified in an HL survivor population known from epidemiological studies to be at high risk of CVS morbidity/mortality. None of the CVS risk calculators identified this high risk. Intriguing data indicate PWV may represent an accessible early indicator of CVS dysfunction. These data prompt comprehensive assessment and management of CVS risk factors in cancer survivors and review of the use of risk calculators in this population.
Acknowledgement/Funding
The Christie NHS Foundation Trust
Collapse
Affiliation(s)
- K Piddock
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - F Britton
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - V Goode
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - E White
- The Christie NHS Foundation Trust, Manchester, United Kingdom
| | - A Greenstein
- University of Manchester, Division of Cardiovascular Sciences, Manchester, United Kingdom
| | - K M Linton
- Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom
| | - J Radford
- University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
| |
Collapse
|
9
|
Radford J, Connors J, Younes A, Gallamini A, Ansell S, Kim W, Cheong J, Flinn I, Kalakonda N, Kaminski M, Pettengell R, Onsum M, Josephson N, Kuroda S, Liu R, Miao H, Gautam A, Trepicchio W, Sureda A. EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON-1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC. Hematol Oncol 2019. [DOI: 10.1002/hon.99_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Radford
- Department of Medical Oncology; University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester United Kingdom
| | - J.M. Connors
- Centre for Lymphoid Cancer; British Columbia Cancer Centre for Lymphoid Cancer; Vancouver Canada
| | - A. Younes
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Gallamini
- Research; Innovation and Statistics Department, A Lacassagne Cancer Centre; Nice France
| | - S.M. Ansell
- Department of Medicine; Mayo Clinic; Rochester United States
| | - W.S. Kim
- Hematology-Oncology; Samsung Medical Center; Seoul Republic of Korea
| | - J. Cheong
- Division of Hematology; Department of Internal Medicine, Yonsei University College of Medicine; Seoul Republic of Korea
| | - I. Flinn
- Department of Oncology; Sarah Cannon Research Institute; Nashville United States
| | - N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - M. Kaminski
- Internal Medicine; University of Michigan; Ann Arbor United States
| | - R. Pettengell
- Haematology; St George's Hospital; London United Kingdom
| | - M. Onsum
- Biomarkers; Seattle Genetics, Inc.; Bothell United States
| | - N. Josephson
- Clinical Development; Seattle Genetics, Inc.; Bothell United States
| | - S. Kuroda
- Biostatistics; Takeda Development Center Japan, Takeda Pharmaceutical Company Limited; Osaka Japan
| | - R. Liu
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - H. Miao
- OTAU Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Gautam
- Global Medical Affairs; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - W.L. Trepicchio
- Translational and Biomarker Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - A. Sureda
- Clinical Hematology; Institut Català d'Oncologia - Hospital Duran i Reynals; Barcelona Spain
| |
Collapse
|
10
|
Collins G, Horwitz S, Hamadani M, Samaniego F, Spira A, Caimi P, Davies A, Menne T, Fields P, Cruz H, He S, Boni J, Feingold J, Wuerthner J, Radford J. ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT-301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL). Hematol Oncol 2019. [DOI: 10.1002/hon.61_2629] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- G. Collins
- Department of Clinical Haematology; Oxford University Hospitals NHS Foundation Trust; Oxford United Kingdom
| | - S. Horwitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - M. Hamadani
- Division of Hematology/Oncology; Medical College of Wisconsin; Milwaukee WI United States
| | - F. Samaniego
- Department of Lymphoma/Myeloma; MD Anderson Cancer Center, The University of Texas; Houston TX United States
| | - A. Spira
- Research Institute; Virginia Cancer Specialists; Fairfax VA United States
| | - P. Caimi
- University Hospitals, Cleveland Medical Center; Case Western Reserve University (CWRU); Cleveland OH United States
| | - A. Davies
- Cancer Research UK Centre; University of Southampton; Southampton United Kingdom
| | - T. Menne
- Cancer Services and Clinical Haematology; The Newcastle upon Tyne Hospitals NHS Foundation Trust; Newcastle United Kingdom
| | - P. Fields
- Department of Haematology; Guy's and St Thomas’ NHS Foundation Trust; London United Kingdom
| | - H. Cruz
- Clinical Research; ADC Therapeutics; Epalinges Switzerland
| | - S. He
- Clinical Development; ADC Therapeutics; Murray Hill NJ United States
| | - J. Boni
- Clinical Development; ADC Therapeutics; Murray Hill NJ United States
| | - J. Feingold
- Clinical Development; ADC Therapeutics; Murray Hill NJ United States
| | - J. Wuerthner
- Clinical Research; ADC Therapeutics; Epalinges Switzerland
| | - J. Radford
- Department of Medical Oncology; The University of Manchester and The Christie NHS Foundation Trust; Manchester United Kingdom
| |
Collapse
|
11
|
Radford J, Kahl B, Hamadani M, Carlo-Stella C, O'Connor O, Ardeshna K, Feingold J, He S, Reid E, Solh M, Chung K, Heffner L, Ungar D, Caimi P. ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT-402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.60_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J. Radford
- Department of Medical Oncology; University of Manchester and The Christie NHS Foundation Trust; Manchester United Kingdom
| | - B. Kahl
- Department of Medicine; Oncology Division, Washington University in St. Louis; St. Louis MO United States
| | - M. Hamadani
- Division of Hematology and Oncology; Medical College of Wisconsin; Milwaukee WI United States
| | - C. Carlo-Stella
- Department of Oncology and Hematology; Humanitas Cancer Center, Humanitas University; Milan Italy
| | - O.A. O'Connor
- Center for Lymphoid Malignancies; NewYork-Presbyterian/Columbia University Irving Medical Center; New York United States
| | - K.M. Ardeshna
- Department of Haematology; University College London Hospitals NHS Foundation Trust; London United Kingdom
| | - J. Feingold
- Clinical Development; ADC Therapeutics; Murray Hill NJ United States
| | - S. He
- Clinical Development; ADC Therapeutics; Murray Hill NJ United States
| | - E. Reid
- Division of Hematology/Oncology; University of California San Diego Health Moores Cancer Center; La Jolla CA United States
| | - M. Solh
- Blood and Marrow Transplant Program; Northside Hospital; Atlanta GA United States
| | - K. Chung
- Department of Hematology and Oncology; Greenville Health System; Greenville SC United States
| | - L. Heffner
- Department of Haematology and Medical Oncology; Winship Cancer Institute, Emory University; Atlanta GA United States
| | - D. Ungar
- Clinical Development; ADC Therapeutics; Murray Hill NJ United States
| | - P. Caimi
- University Hospitals Cleveland Medical Center; Case Western Reserve University (CWRU); Cleveland OH United States
| |
Collapse
|
12
|
Morschhauser F, Tilly H, Chaidos A, Phillips T, Ribrag V, Campbell P, Ghandi Laurent D, Jurczak W, McKay P, Opat S, Radford J, Rajarethinam A, Yang J, Howell H, Newberry K, Adib D, Salles G. INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.111_2629] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- F. Morschhauser
- Hematology-Transfusion; Centre Hospitalier Universitaire; Lille France
| | - H. Tilly
- Hematology; Centre de Lutte Contre le Cancer Henri Becquerel; Rouen France
| | - A. Chaidos
- Medicine, Centre for Haematology, Department of Medicine, Imperial College London, Imperial College Healthcare NHS Trust; Hammersmith Hospital; London United Kingdom
| | - T. Phillips
- Hematology and Oncology; University of Michigan; Ann Arbor United States
| | - V. Ribrag
- DITEP; Gustave Roussy; Villejuif France
| | - P. Campbell
- Hematology; Barwon Health; Geelong Australia
| | - D. Ghandi Laurent
- Hematology; Hematology Institute University Hospital School of Medicine; Caen France
| | | | - P. McKay
- Hematology; Beatson West of Scotland Cancer Centre; Glasgow United Kingdom
| | - S. Opat
- Hematology; Monash University; Clayton Australia
| | - J. Radford
- Medical Oncology; University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester United Kingdom
| | | | - J. Yang
- Biostatistics; Epizyme; Cambridge United States
| | - H. Howell
- Clinical Operations; Epizyme; Cambridge United States
| | | | - D. Adib
- Clinical Development; Epizyme; Cambridge United States
| | - G. Salles
- Hematology; Lyon-Sud Hospital Centre; Pierre-Bénite France
| |
Collapse
|
13
|
Karlsson I, Traub S, Järås K, Edwards D, Gramming E, Lindell Andersson M, To Y, Mårtensson L, Teige I, Acton G, Dyer M, Radford J, Collins G, Jerkeman M, Frendéus B, McAllister A, Davies A. PHASE 1/2A CLINICAL TRIALS OF BI-1206, A MONOCLONAL ANTIBODY TO FCΓRIIB, ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH B-CELL MALIGNANCIES. Hematol Oncol 2019. [DOI: 10.1002/hon.206_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- I. Karlsson
- Preclinical Research; BioInvent International AB; Lund Sweden
| | - S. Traub
- Centre for Drug Development; Cancer Research UK; London United Kingdom
| | - K. Järås
- Clinical Development; BioInvent International AB; Lund Sweden
| | - D. Edwards
- Centre for Drug Development; Cancer Research UK; London United Kingdom
| | - E. Gramming
- Clinical Development; BioInvent International AB; Lund Sweden
| | | | - Y. To
- Centre for Drug Development; Cancer Research UK; London United Kingdom
| | - L. Mårtensson
- Preclinical Research; BioInvent International AB; Lund Sweden
| | - I. Teige
- Preclinical Research; BioInvent International AB; Lund Sweden
| | - G. Acton
- Centre for Drug Development; Cancer Research UK; London United Kingdom
| | - M.J. Dyer
- Ernest and Helen Scott Haematological Research Institute; University of Leicester; Leicester United Kingdom
| | - J. Radford
- Institute of Cancer Sciences; University of Manchester; Manchester United Kingdom
| | - G.P. Collins
- Oxford Cancer and Haematology Centre; Churchill Hospital; Oxford United Kingdom
| | - M. Jerkeman
- Department of Oncology; Skane University Hospital; Lund Sweden
| | - B. Frendéus
- Preclinical Research; BioInvent International AB; Lund Sweden
| | - A. McAllister
- Clinical Development; BioInvent International AB; Lund Sweden
| | - A. Davies
- University of Southampton; Cancer Research UK Centre; Southampton United Kingdom
| |
Collapse
|
14
|
Shustov A, Cabrera M, Bellei M, Civallero M, Ko Y, Manni M, Horwitz S, Antonio De Souza C, Radford J, Varela S, Prates M, Ferreri A, Chiattone C, Spina M, Vose J, Chiappella A, Laszlo D, Marino D, Stelitano C, Skrypets T, Federico M. ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE: ANALYSIS OF 235 CASES COLLECTED BY THE T-CELL PROJECT. Hematol Oncol 2019. [DOI: 10.1002/hon.93_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Shustov
- Division of Hematology; University of Washington Medical Center; Seattle United States
| | - M. Cabrera
- Seccion Hematologia; Hospital del Salvador, Universidad de Chile; Santiago Chile
| | - M. Bellei
- Department of Diagnostic; Clinical, and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| | - M. Civallero
- Department of Diagnostic; Clinical, and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| | - Y.H. Ko
- Department of Pathology; Sungkyunkwan University; Seoul Republic of Korea
| | - M. Manni
- Department of Diagnostic; Clinical, and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| | - S.M. Horwitz
- Department of Medical Oncology; Memorial Sloan-Kettering Cancer Ctr; New York United States
| | - C. Antonio De Souza
- Centro de Hematologia e Hemoterapia; University of Campinas; Campinas Brazil
| | - J. Radford
- Manchester Academic Health Science Centre; University of Manchester and the Christie NHS Foundation Trust; Manchester United Kingdom
| | - S.B. Varela
- Hospital Vall D/Hebron; University Hospital Vall D/Hebron; Barcelona Spain
| | - M.V. Prates
- Gatla; Laboratorio Varifarma sa; Buenos Aires Argentina
| | - A. Ferreri
- Unit of Lymphoid Malignancies; IRCCS San Raffaele Scientific Institute; Milan Italy
| | - C. Chiattone
- Hematology Division; Santa Casa Medical School; São Paulo Brazil
| | - M. Spina
- Centro Di Riferimento Oncologico; Aviano Italy
| | - J.M. Vose
- Division of Oncology & Hematology; University of Nebraska Medical Center; Omaha NE United States
| | - A. Chiappella
- Hematology Division; Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - D. Laszlo
- Division of Haemato-Oncology; Istituto Europeo di Oncologia; Milan Italy
| | - D. Marino
- Department of Clinical and Experimental Oncology; Veneto Institute of Oncology IOV-IRCCS Padova; Padua Italy
| | - C. Stelitano
- Department of Haematology; Grande Ospedale Metropolitano Bianchi Melacrino Morelli; Reggio Calabria Italy
| | - T. Skrypets
- Department of Diagnostic; Clinical, and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Department of Diagnostic; Clinical, and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| |
Collapse
|
15
|
Garnett ST, Butchart SHM, Baker GB, Bayraktarov E, Buchanan KL, Burbidge AA, Chauvenet ALM, Christidis L, Ehmke G, Grace M, Hoccom DG, Legge SM, Leiper I, Lindenmayer DB, Loyn RH, Maron M, McDonald P, Menkhorst P, Possingham HP, Radford J, Reside AE, Watson DM, Watson JEM, Wintle B, Woinarski JCZ, Geyle HM. Metrics of progress in the understanding and management of threats to Australian birds. Conserv Biol 2019; 33:456-468. [PMID: 30465331 DOI: 10.1111/cobi.13220] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Revised: 06/14/2018] [Accepted: 08/03/2018] [Indexed: 06/09/2023]
Abstract
Although evidence-based approaches have become commonplace for determining the success of conservation measures for the management of threatened taxa, there are no standard metrics for assessing progress in research or management. We developed 5 metrics to meet this need for threatened taxa and to quantify the need for further action and effective alleviation of threats. These metrics (research need, research achievement, management need, management achievement, and percent threat reduction) can be aggregated to examine trends for an individual taxon or for threats across multiple taxa. We tested the utility of these metrics by applying them to Australian threatened birds, which appears to be the first time that progress in research and management of threats has been assessed for all threatened taxa in a faunal group at a continental scale. Some research has been conducted on nearly three-quarters of known threats to taxa, and there is a clear understanding of how to alleviate nearly half of the threats with the highest impact. Some management has been attempted on nearly half the threats. Management outcomes ranged from successful trials to complete mitigation of the threat, including for one-third of high-impact threats. Progress in both research and management tended to be greater for taxa that were monitored or occurred on oceanic islands. Predation by cats had the highest potential threat score. However, there has been some success reducing the impact of cat predation, so climate change (particularly drought), now poses the greatest threat to Australian threatened birds. Our results demonstrate the potential for the proposed metrics to encapsulate the major trends in research and management of both threats and threatened taxa and provide a basis for international comparisons of evidence-based conservation science.
Collapse
Affiliation(s)
- S T Garnett
- Threatened Species Recovery Hub, National Environmental Science Program, Research Institute for the Environment and Livelihoods, Charles Darwin University, Northern Territory, 0909, Australia
| | - S H M Butchart
- BirdLife International, David Attenborough Building, Pembroke Street, Cambridge, CB2 3QZ, U.K
- Department of Zoology, The University of Cambridge, Downing Street, Cambridge, CB2 3EJ, U.K
| | - G B Baker
- Institute for Marine and Antarctic Studies, The University of Tasmania, Hobart, Tasmania, 7005, Australia
| | - E Bayraktarov
- Threatened Species Recovery Hub, National Environmental Science Program, Centre for Biodiversity and Conservation Science, The University of Queensland, St Lucia, Qld, 4072, Australia
| | - K L Buchanan
- School of Life and Environmental Sciences, Deakin University, 75 Pigdons Road, Geelong, Victoria, 3216, Australia
| | - A A Burbidge
- 87 Rosedale Street, Floreat, Western Australia, 6014, Australia
| | - A L M Chauvenet
- School of Environment and Science & Environmental Futures Research Institute, Griffith University, Gold Coast, Queensland, 4222, Australia
| | - L Christidis
- National Marine Science Centre, Southern Cross University, Lismore, New South Wales, 2480, Australia
| | - G Ehmke
- Threatened Species Recovery Hub, National Environmental Science Program, Centre for Biodiversity and Conservation Science, The University of Queensland, St Lucia, Qld, 4072, Australia
- BirdLife Australia, Carlton, Victoria, 3053, Australia
| | - M Grace
- Department of Zoology, The University of Oxford, Oxford, OX1 3PS, U.K
| | - D G Hoccom
- Royal Society for the Protection of Birds, Bedfordshire, SG 19 2DL, U.K
| | - S M Legge
- Threatened Species Recovery Hub, National Environmental Science Program, Centre for Biodiversity and Conservation Science, The University of Queensland, St Lucia, Qld, 4072, Australia
- Threatened Species Recovery Hub, National Environmental Science Program, Fenner School of Environment and Society, The Australian National University, Canberra, Australian Capital Territory, 2601, Australia
| | - I Leiper
- Threatened Species Recovery Hub, National Environmental Science Program, Research Institute for the Environment and Livelihoods, Charles Darwin University, Northern Territory, 0909, Australia
| | - D B Lindenmayer
- Threatened Species Recovery Hub, National Environmental Science Program, Fenner School of Environment and Society, The Australian National University, Canberra, Australian Capital Territory, 2601, Australia
| | - R H Loyn
- The Centre for Freshwater Ecosystems, School of Life Sciences, La Trobe University, Wodonga, Victoria, 3690, Australia
- Institute for Land, Water and Society, Charles Sturt University, Albury, New South Wales, 2640, Australia
- Eco Insights, Beechworth, Victoria, 3747, Australia
| | - M Maron
- Threatened Species Recovery Hub, National Environmental Science Program, Centre for Biodiversity and Conservation Science, The University of Queensland, St Lucia, Qld, 4072, Australia
- School of Earth and Environmental Sciences, The University of Queensland, St Lucia, 4072, Australia
| | - P McDonald
- Zoology, School of Environmental and Rural Science, University of New England, Armidale, New South Wales, 2351, Australia
| | - P Menkhorst
- Arthur Rylah Institute for Environmental Research, Department of Environment, Land, Water and Planning, Heidelberg, Victoria, 3084, Australia
| | - H P Possingham
- Threatened Species Recovery Hub, National Environmental Science Program, Centre for Biodiversity and Conservation Science, The University of Queensland, St Lucia, Qld, 4072, Australia
- The Nature Conservancy, Arlington, VA, 22203-1606, U.S.A
| | - J Radford
- Department of Ecology, Environment and Evolution, La Trobe University, Bundoora, Victoria, 3086, Australia
- Research Centre for Future Landscapes, La Trobe University, Bundoora, Victoria, 3086, Australia
| | - A E Reside
- Threatened Species Recovery Hub, National Environmental Science Program, Centre for Biodiversity and Conservation Science, The University of Queensland, St Lucia, Qld, 4072, Australia
| | - D M Watson
- Institute for Land, Water and Society, Charles Sturt University, Albury, New South Wales, 2640, Australia
| | - J E M Watson
- Threatened Species Recovery Hub, National Environmental Science Program, Centre for Biodiversity and Conservation Science, The University of Queensland, St Lucia, Qld, 4072, Australia
- School of Earth and Environmental Sciences, The University of Queensland, St Lucia, 4072, Australia
- Wildlife Conservation Society, Bronx, NY, 10460-1068, U.S.A
| | - B Wintle
- School of Bioscience, The University of Melbourne, Parkville, Victoria, 3010, Australia
| | - J C Z Woinarski
- Threatened Species Recovery Hub, National Environmental Science Program, Research Institute for the Environment and Livelihoods, Charles Darwin University, Northern Territory, 0909, Australia
| | - H M Geyle
- Threatened Species Recovery Hub, National Environmental Science Program, Research Institute for the Environment and Livelihoods, Charles Darwin University, Northern Territory, 0909, Australia
| |
Collapse
|
16
|
Kühnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Ann Oncol 2017; 28:1540-1546. [PMID: 28398499 PMCID: PMC5815562 DOI: 10.1093/annonc/mdx128] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI R-CHOP14v21 randomized phase 3 trial did not demonstrate a difference in outcomes between R-CHOP-14 and R-CHOP-21 in newly diagnosed DLBCL patients aged 19-88 years, but data on elderly patients have not been reported in detail so far. Here, we provide a subgroup analysis of patients ≥60 years treated on the R-CHOP14v21 trial with extended follow-up. PATIENTS AND METHODS Six hundred and four R-CHOP14v21 patients ≥60 years were included in this subgroup analysis, with a median follow-up of 77.7 months. To assess the impact of MYC rearrangements (MYC-R) and double-hit-lymphoma (DHL) on outcome in elderly patients, we performed a joint analysis of cases with available molecular data from the R-CHOP14v21 (N = 217) and RICOVER-60 (N = 204) trials. RESULTS Elderly DLBCL patients received high dose intensities with median total doses of ≥98% for all agents. Toxicities were similar in both arms with the exception of more grade ≥3 neutropenia (P < 0.0001) and fewer grade ≥3 thrombocytopenia (P = 0.05) in R-CHOP-21 versus R-CHOP-14. The elderly patient population had a favorable 5-year overall survival (OS) of 69% (95% CI: 65-73). We did not identify any subgroup of patients that showed differential response to either regimen. In multivariable analysis including individual factors of the IPI, gender, bulk, B2M and albumin levels, only age and B2M were of independent prognostic significance for OS. Molecular analyses demonstrated a significant impact of MYC-R (HR = 1.96; 95% CI: 1.22-3.16; P = 0.01) and DHL (HR = 2.21; 95% CI: 1.18-4.11; P = 0.01) on OS in the combined trial cohorts, independent of other prognostic factors. CONCLUSIONS Our data support equivalence of both R-CHOP application forms in elderly DLBCL patients. Elderly MYC-R and DHL patients have inferior prognosis and should be considered for alternative treatment approaches. TRIAL NUMBERS ISCRTN 16017947 (R-CHOP14v21); NCT00052936 (RICOVER-60).
Collapse
MESH Headings
- Age Factors
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived/administration & dosage
- Antibodies, Monoclonal, Murine-Derived/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Biomarkers, Tumor/genetics
- Cyclophosphamide/administration & dosage
- Cyclophosphamide/adverse effects
- Doxorubicin/administration & dosage
- Doxorubicin/adverse effects
- Drug Administration Schedule
- Female
- Gene Rearrangement
- Humans
- Kaplan-Meier Estimate
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/mortality
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Middle Aged
- Multivariate Analysis
- Patient Selection
- Precision Medicine
- Prednisone/administration & dosage
- Prednisone/adverse effects
- Proto-Oncogene Proteins c-bcl-2/genetics
- Proto-Oncogene Proteins c-bcl-6/genetics
- Proto-Oncogene Proteins c-myc/genetics
- Risk Factors
- Rituximab
- Time Factors
- Treatment Outcome
- United Kingdom
- Vincristine/administration & dosage
- Vincristine/adverse effects
Collapse
Affiliation(s)
- A. Kühnl
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - D. Cunningham
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
| | - N. Counsell
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - E. A. Hawkes
- Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey
- Olivia-Newton John Cancer Research & Wellness Centre, Melbourne, Australia
| | - W. Qian
- Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge
| | - P. Smith
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - N. Chadwick
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - A. Lawrie
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - P. Mouncey
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - A. Jack
- HMDS, St James’s Institute of Oncology, Leeds
| | | | - K. M. Ardeshna
- Department of Hematology, University College London, London
- Mount Vernon Cancer Centre, Northwood
| | - J. Radford
- Department of Medical Oncology, University of Manchester and the Christie NHS Foundation Trust, Manchester
| | - A. McMillan
- Department of Hematology, Nottingham City Hospital, Nottingham
| | | | - D. Turner
- Department of Hematology, Torbay Hospital, Torquay
| | | | - P. W. Johnson
- Cancer Research UK Center, University of Southampton, Southampton, UK
| | - J. Gambell
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
| | - A. Rosenwald
- Institute of Pathology, Würzburg University, Würzburg
| | - G. Ott
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart
| | - H. Horn
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Stuttgart
| | - M. Ziepert
- Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig
| | - M. Pfreundschuh
- Department of Medicine, Saarland University Medical School, Homburg/Saar, Germany
| | - D. Linch
- Department of Hematology, University College London, London
| |
Collapse
|
17
|
Blakemore S, Daigle S, McDonald A, Morschhauser F, Ribrag V, Salles G, McKay P, Tilly H, Schmitt A, Le Gouill S, Fruchart C, Radford J, Zinzani P, Assouline S, Cartron G, Dickinson M, Morin R, Wu H, Sausen M, Clawson A, Ho P, Miao H. PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_14] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
| | | | | | - F. Morschhauser
- Department of Hematology; Centre Hospitalier Universitaire; Lille France
| | - V. Ribrag
- Haematology; Gustave Roussy; Villejuif France
| | - G. Salles
- Hematology; Lyon-Sud Hospital Center; Pierre-Bénite France
| | - P. McKay
- Haematology; North Glasgow University Hospitals; Glasgow UK
| | - H. Tilly
- Hematology; Centre de lutte Contre le Cancer Henri Becquerel; Rouen France
| | - A. Schmitt
- Hematology; Institut Bergonié; Bordeaux France
| | - S. Le Gouill
- Service d'Hématologie Clinique; Universite De Nantes; Nantes France
| | - C. Fruchart
- Hematologie; Centre François Baclesse; Caen France
| | - J. Radford
- Molecular & Clinical Cancer Sciences (L5); The University of Manchester; Manchester UK
| | - P.L. Zinzani
- Hematology; University of Bologna; Bologna Italy
| | | | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | - M. Dickinson
- Department of Haematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - R. Morin
- Molecular Biology and Biochemistry; Simon Fraser University; Burnaby BC Canada
| | - H. Wu
- Genomics and Oncology; Roche Molecular Systems; Pleasanton CA USA
| | - M. Sausen
- Research and Development; Personal Genome Diagnostics; Baltimore MD USA
| | - A. Clawson
- Biostatistics; Epizyme; Morrisville NC USA
| | - P.T. Ho
- Oncology Clinical Development; Epizyme; Cambridge MA USA
| | - H. Miao
- Oncology Clinical Development; Epizyme; Cambridge MA USA
| |
Collapse
|
18
|
Trotman J, Fosså A, Federico M, Stevens L, Kirkwood A, Clifton-Hadley L, Patrick P, Berkahn L, D'Amore F, Enblad G, Luminari S, Radford J, Barrington S, Johnson P. RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_53] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- J. Trotman
- Haematology, Concord Repatriation General Hospital; University of Sydney; Concord Australia
| | - A. Fosså
- Medical Oncology; Oslo University Hospital; Oslo Norway
| | - M. Federico
- Diagnostic Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Missouri Italy
| | - L. Stevens
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - A. Kirkwood
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - L. Clifton-Hadley
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - P. Patrick
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - L. Berkahn
- Haematology; Auckland City Hospital; Auckland New Zealand
| | - F. D'Amore
- Haematology; Aarhus University Hospital; Aarhus C Denmark
| | - G. Enblad
- Immunology, Genetics and Pathology; Uppsala University; Uppsala Sweden
| | - S. Luminari
- Arcispedale Santa Maria Nuova; Istituti di Ricovero e Cura a Carattere Scientifico; Reggio Emilia Italy
| | - J. Radford
- Medical Oncology; Christie Hospital; Manchester UK
| | - S.F. Barrington
- The PET Imaging Centre, King's College London; King's Health Partners, St. Thomas' Hospital; London UK
| | - P. Johnson
- Cancer Research UK Centre; University of Southampton; Southampton UK
| |
Collapse
|
19
|
Morschhauser F, Salles G, McKay P, Tilly H, Schmitt A, Gerecitano J, Johnson P, Le Gouill S, Dickinson M, Fruchart C, Lamy T, Chaidos A, Jurczak W, Opat S, Radford J, Zinzani P, Assouline S, Cartron G, Clawson A, Picazio N, Ribich S, Blakemore S, Larus J, Miao H, Ho P, Ribrag V. INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_3] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- F. Morschhauser
- Department of Hematology; Centre Hospitalier Universitaire; Lille France
| | - G. Salles
- Hematology; Lyon-Sud Hospital Center; Pierre-Bénite France
| | - P. McKay
- Haematology; North Glasgow University Hospitals; Glasgow UK
| | - H. Tilly
- Hematology; Centre de lutte Contre le Cancer Henri Becquerel; Rouen France
| | - A. Schmitt
- Hematology; Institut Bergonié; Bordeaux France
| | - J. Gerecitano
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Johnson
- Medical Oncology; Southampton General Hospital; Southampton UK
| | - S. Le Gouill
- Service d'Hématologie Clinique; Universite De Nantes; Nantes France
| | - M.J. Dickinson
- Department of Haematology; Peter MacCallum Cancer Centre; Melbourne Australia
| | - C. Fruchart
- Hematologie; Centre François Baclesse; Caen France
| | - T. Lamy
- Service d'Hématologie Clinique; CHU de Rennes; Rennes France
| | - A. Chaidos
- Haematology; Hammersmith Hospital; London UK
| | | | - S. Opat
- Clinical Haematology; Monash University; Clayton Australia
| | - J. Radford
- Molecular & Clinical Cancer Sciences (L5); The University of Manchester; Manchester UK
| | - P.L. Zinzani
- Hematology; University of Bologna; Bologna Italy
| | | | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | | | - N. Picazio
- Clinical Operations; Epizyme; Cambridge USA
| | - S. Ribich
- Biological Sciences; Epizyme; Cambridge USA
| | | | - J. Larus
- Clinical Data Sciences; Epizyme; Cambridge USA
| | - H. Miao
- Oncology Clinical Development; Epizyme; Cambridge USA
| | - P.T. Ho
- Oncology Clinical Development; Epizyme; Cambridge USA
| | - V. Ribrag
- Haematology; Gustave Roussy; Villejuif France
| |
Collapse
|
20
|
Pike L, Kirkwood A, Patrick P, Radford J, Burton C, Stevens L, Clifton-Hadley L, Johnson P, Barrington S. CAN BASELINE PET-CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_18] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L.C. Pike
- KCL and Guys'& St Thomas' PET Centre; Division of Imaging and Biomedical Engineering, Kings College London; London UK
| | - A.A. Kirkwood
- Cancer Research UK and UCL Cancer Trials Centre; University College London; London UK
| | - P. Patrick
- Cancer Research UK and UCL Cancer Trials Centre; University College London; London UK
| | - J. Radford
- Division of Molecular & Clinical Cancer Sciences; University of Manchester and The Christie NHS Foundation Trust; Manchester UK
| | - C. Burton
- Haematological Malignancy Diagnostic Service; University of Leeds; Leeds
| | - L. Stevens
- Cancer Research UK and UCL Cancer Trials Centre; University College London; London UK
| | - L. Clifton-Hadley
- Cancer Research UK and UCL Cancer Trials Centre; University College London; London UK
| | - P.W. Johnson
- University of Southampton; Cancer Research UK Centre; Southampton UK
| | - S.F. Barrington
- KCL and Guys'& St Thomas' PET Centre; Division of Imaging and Biomedical Engineering, Kings College London; London UK
| |
Collapse
|
21
|
Zinzani P, Fanale M, Chen R, Armand P, Johnson N, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos T, Tomita A, von Tresckow B, Shipp M, Zhang Y, Balakumaran A, Moskowitz C. PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_125] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- P.L. Zinzani
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES); Institute of Hematology “L. e A. Seràgnoli,” University of Bologna; Bologna Italy
| | - M.A. Fanale
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - R. Chen
- Department of Hematology & Hematopoietic Cell Transplantation; City of Hope National Medical Center; Duarte USA
| | - P. Armand
- Department of Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| | - N. Johnson
- Division of Hematology; Jewish General Hospital; Montreal Canada
| | - P. Brice
- Department of Hematologic Oncology; Hôpital Saint-Louis; Paris France
| | - J. Radford
- Division of Molecular & Clinical Cancer Sciences; The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester UK
| | - V. Ribrag
- Department of Haematological Cancer; Institut Gustave Roussy; Villejuif France
| | - D. Molin
- Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology; Uppsala University; Uppsala Sweden
| | - T.P. Vassilakopoulos
- Department of Haematology & Bone Marrow Transplantation; National and Kapodistrian University of Athens, Laikon General Hospital; Athens Greece
| | - A. Tomita
- Department of Hematology & Oncology; Nagoya University Graduate School of Medicine *Current affiliation: Fujita Health University School of Medicine, Toyoake, Japan; Nagoya Japan
| | - B. von Tresckow
- Department of Internal Medicine; University Hospital Cologne; Cologne Germany
| | - M.A. Shipp
- Department of Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| | - Y. Zhang
- Department of Biostatistics; LDS Oncology, Merck & Co., Inc.; Kenilworth USA
| | - A. Balakumaran
- Department of Oncology Clinical Development; Merck & Co., Inc.; Kenilworth USA
| | - C.H. Moskowitz
- Department of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
22
|
Kaplan J, Gordon L, Infante J, Popat R, Rambaldi A, Madan S, Patel M, Gritti G, El-Sharkawi D, Chau I, Radford J, Perez De Oteyza J, Zinzani P, Iyer S, Faucette S, Sheldon-Waniga E, Stumpo K, Shou Y, Carpio C, Bosch F. TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_60] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- J. Kaplan
- Department of Medicine; Northwestern University; Chicago USA
| | - L. Gordon
- Robert H Lurie Comprehensive Cancer Center; Northwestern University Feinberg School of Medicine; Chicago USA
| | - J. Infante
- Drug Development Unit; Sarah Cannon Research Institute/Tennessee Oncology; Nashville USA
| | - R. Popat
- NIHR Clinical Research Facility; UCLH; London UK
| | - A. Rambaldi
- Dipartimento di Oncologia ed Emato-Oncologia / Hematology and Bone Marrow Transplant Unit; Università degli Studi di Milano / Ospedale Papa Giovanni XXII; Bergamo Italy
| | - S. Madan
- Dipartimento di Oncologia ed Emato-Oncologia/Hematology and Bone Marrow Transplant Unit; Università degli Studi di Milano/Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - M.R. Patel
- Hematology-Oncology; Florida Cancer Specialists/Sarah Cannon Research Institute; Sarasota USA
| | - G. Gritti
- Hematology and Bone Marrow Transplant Unit; Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - D. El-Sharkawi
- Haematology; NIHR UCLH Clinical Research Facility; London UK
| | - I. Chau
- Department of Medicine; Royal Marsden Hospital; Surrey UK
| | - J. Radford
- Manchester Academic Health Science Centre; University of Manchester and the Christie NHS Foundation Trust; Manchester UK
| | | | - P. Zinzani
- Hematology, Institute of Hematology “Seragnoli”; University of Bologna; Bologna Italy
| | - S. Iyer
- Advanced Therapeutics, Institute of Academic Medicine; Houston Methodist Cancer Center; Houston USA
| | - S. Faucette
- Clinical Pharmacology; Takeda Pharmaceuticals International Co.; Cambridge USA
| | | | - K. Stumpo
- Oncology Clinical Research; Takeda Pharmaceuticals; Cambridge USA
| | - Y. Shou
- Oncology Clinical Research; Takeda Pharmaceuticals International Co.; Cambridge USA
| | - C. Carpio
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | - F. Bosch
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| |
Collapse
|
23
|
Gibb A, Pirrie S, Linton K, Paterson K, Davies A, Collins G, Menne T, McKay P, Fields P, Miall F, Nagy E, Wheatley K, Warbey V, Barrington S, Radford J. RESULTS OF a PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_68] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- A. Gibb
- Christie Hospital; The Christie NHS Foundation Trust; Manchester UK
| | - S. Pirrie
- CRCTU, Part of the Bloodwise Funded Trials Acceleration Programme; University of Birmingham; Birmingham UK
| | - K. Linton
- Manchester Academic Health Science Centre; University of Manchester and The Christie NHS Foundation Trust; Manchester UK
| | - K. Paterson
- CRCTU, Part of the Bloodwise Funded Trials Acceleration Programme; University of Birmingham; Birmingham UK
| | - A. Davies
- Cancer Research UK Centre, Cancer Sciences Unit, Faculty of Medicine; University of Southampton; Southampton UK
| | - G. Collins
- Churchill Hospital; Oxford University Hospitals NHS Foundation Trust; Oxford UK
| | - T. Menne
- Freeman Hospital; Newcastle upon Tyne Hospitals NHS Foundation Trust; Newcastle UK
| | - P. McKay
- Haematology; The Beatson West of Scotland Cancer Centre; Glasgow UK
| | - P. Fields
- Guy's Hospital; Guy's and St Thomas' NHS Foundation Trust; London UK
| | - F. Miall
- Leicester Royal Infirmary; University Hospitals of Leicester NHS Foundation Trust; Leicester UK
| | - E. Nagy
- CRCTU, Part of the Bloodwise Funded Trials Acceleration Programme; University of Birmingham; Birmingham UK
| | - K. Wheatley
- CRCTU, Part of the Bloodwise Funded Trials Acceleration Programme; University of Birmingham; Birmingham UK
| | - V. Warbey
- KCL and Guys' & St Thomas PET Imaging Centre, Division of Imaging and Biomedical Engineering; Kings College London; London UK
| | - S. Barrington
- KCL and Guys' & St Thomas PET Imaging Centre, Division of Imaging and Biomedical Engineering; Kings College London; London UK
| | - J. Radford
- Manchester Academic Health Science Centre; University of Manchester and The Christie NHS Foundation Trust; Manchester UK
| |
Collapse
|
24
|
Chen R, Gibb A, Collins G, Popat R, El-Sharkawi D, Burton C, Lewis D, Miall F, Forgie A, Compagnoni A, Andreola G, Brar S, Thall A, Woolfson A, Radford J. BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI-PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_54] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R. Chen
- Hematology/HCT; City of Hope Medical Center; Duarte USA
| | - A.L. Gibb
- Medical Oncology; The Christie NHS Foundation Trust; Withington, Manchester UK
| | - G.P. Collins
- Clinical Haematology; Oxford University Hospitals; Oxford UK
| | - R. Popat
- NIHR UCLH Clinical Research Facility; University College London Hospitals NHS Trust; London UK
| | - D. El-Sharkawi
- NIHR UCLH Clinical Research Facility; University College London Hospitals NHS Trust; London UK
| | - C. Burton
- Haematology; Leeds Teaching Hospitals NHS Trust; Leeds UK
| | - D. Lewis
- Haematology; Derriford Hospital Plymouth; Plymouth UK
| | - F.M. Miall
- Haematology; University Hospitals Leicester; Leicester UK
| | - A. Forgie
- Oncology; Pfizer Inc.; San Francisco USA
| | | | | | - S. Brar
- Clinical Pharmacology; Pfizer Inc.; La Jolla USA
| | - A. Thall
- Global Product Development; Pfizer Inc; La Jolla USA
| | - A. Woolfson
- Pfizer, Inc.; Senior Director & Global Clinical Leader Early and Late Stage I-O Hematology; New York USA
| | - J. Radford
- Manchester Academic Health Science Centre; University of Manchester and the Christie NHS Foundation Trust; Manchester UK
| |
Collapse
|
25
|
Preston A, Kirkwood A, Federico M, Trotman J, Fossa A, Stevens L, Clifton-Hadley L, Patrick P, Berkahn L, d'Amore F, Enblad G, Luminari S, Radford J, Johnson P. OUTCOMES OF TREATMENT FOR OBESE PATIENTS WITH ADVANCED HODGKIN LYMPHOMA IN THE RATHL TRIAL (CRUK/07/033). Hematol Oncol 2017. [DOI: 10.1002/hon.2438_31] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. Preston
- Pharmacy; University Hospitals Bristol; Bristol UK
| | - A. Kirkwood
- Cancer Research UK & UCL Cancer Trials Centre; University College London; London UK
| | - M. Federico
- Diagnostic Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - J. Trotman
- Haematology, Concord Repatriation General Hospital; University of Sydney; Concord Australia
| | - A. Fossa
- Medical Oncology; Oslo University Hospital; Oslo Norway
| | - L. Stevens
- Cancer Research UK & UCL Cancer Trials Centre; University College London; London UK
| | - L. Clifton-Hadley
- Cancer Research UK & UCL Cancer Trials Centre; University College London; London UK
| | - P. Patrick
- Cancer Research UK & UCL Cancer Trials Centre; University College London; London UK
| | - L. Berkahn
- Haematology; Auckland City Hospital; Auckland New Zealand
| | - F. d'Amore
- Haematology; Aarhus University Hospital; Aarhus C Denmark
| | - G. Enblad
- Immunology, Genetics and Pathology; Uppsala University; Uppsala Sweden
| | - S. Luminari
- Arcispedale Santa Maria Nuova; Istituti di Ricovero e Cura a Carattere Scientifico; Reggio Emilia Italy
| | - J. Radford
- Medical Oncology; Christie Hospital; Manchester UK
| | - P.W. Johnson
- Cancer Research UK Centre; University of Southampton; Southampton UK
| |
Collapse
|
26
|
Fowler N, Gopal A, Schuster S, Trotman J, Hess G, Hou J, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Osmanov D, Caballero D, Deshpande S, Vermeulen J, Damle R, Schaffer M, Balasubramanian S, Cheson B, Salles G. Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_75] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- N. Fowler
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - A.K. Gopal
- Seattle Cancer Care Alliance; The University of Washington/Fred Hutchison Cancer Research Center; Seattle USA
| | - S.J. Schuster
- Lymphoma Program; Abramson Cancer Center of the University of Pennsylvania; Philadelphia USA
| | - J. Trotman
- Concord Hospital; University of Sydney, Haematology Department; Sydney Australia
| | - G. Hess
- Department of Hematology/Oncology; Johannes Gutenberg University; Mainz Germany
| | - J. Hou
- Division of Hematology/Oncology; University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute; Pittsburgh USA
| | - A. Yacoub
- Hematologic Malignancies and Cellular Therapeutics; University of Kansas Medical Center; Kansas City USA
| | - M. Lill
- Stem Cell and Bone Marrow Transplant Program, Cedars-Sinai Medical Center; Los Angeles USA
| | - P. Martin
- Weill Cornell Medical College; Cornell University; New York USA
| | - U. Vitolo
- Hematology; Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - A. Spencer
- Central Clinical School; Alfred Hospital-Monash University; Melbourne Australia
| | - J. Radford
- University of Manchester and the Christie NHS Foundation Trust; Manchester Academic Health Science Centre; Manchester UK
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - J. Morton
- Clinical Haemato-Oncology; Haematology and Oncology Clinics of Australia; Milton Australia
| | - D. Osmanov
- Blokhin Cancer Research Center; Russian Academy of Medical Sciences; Moscow Russian Federation
| | - D. Caballero
- Instituto Biosanitario de Salamanca; Hospital Clínico Universitario; Salamanca Spain
| | | | - J. Vermeulen
- Research & Development, Janssen; Leiden The Netherlands
| | - R. Damle
- Research & Development, Janssen; Raritan USA
| | - M. Schaffer
- Research & Development, Janssen; Raritan USA
| | | | - B. Cheson
- Lombardi Comprehensive Cancer Center; Georgetown University Hospital; Washington District of Columbia USA
| | - G. Salles
- Haematology Department; Hospices Civils de Lyon-Université de Lyon; Lyon France
| |
Collapse
|
27
|
Radford J, Gribben J, Johnson P, Malladi R, Neeson S, Asfaw B, O'Regan L, Law A, Ringrose C, Brownlow R, Jackson A, Nolan C, Nolan C. YourTreatmentChoices: FAST ACCESS TO TRIALS PROGRAMME. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J. Radford
- Department of Medical Oncology; University of Manchester and The Christie NHS Foundation Trust; Manchester UK
| | - J. Gribben
- Centre for Haemato-Oncology; Barts Cancer Institute; London UK
| | - P.W. Johnson
- Cancer Research UK Centre; University of Southampton; Southampton UK
| | - R. Malladi
- Centre for Clinical Haematology; University Hospitals Birmingham NHS Foundation Trust; Birmingham UK
| | - S. Neeson
- Division of Research and Education; The University of Manchester and the Christie NHS Foundation Trust; Manchester UK
| | - B. Asfaw
- Centre for Clinical Haematology; University Hospitals Birmingham NHS Foundation Trust; Birmingham UK
| | - L. O'Regan
- Medical School, St Georges NHS Foundation Trust; St Georges & Kingston University of London; Kingston upon Thames UK
| | - A. Law
- Barts Cancer Institute; Queen Mary University of London, St Bartholomews Hospital, Barts Health NHS Trust; London UK
| | - C. Ringrose
- Cancer Research UK Centre; University of Southampton; Southampton UK
| | | | | | - C. Nolan
- The Innovation Centre for Tomorrow's Medicines; Tomorrow's Medicines Ltd; Daresbury UK
| | - C. Nolan
- The Innovation Centre for Tomorrow's Medicines; Tomorrow's Medicines Ltd; Daresbury UK
| |
Collapse
|
28
|
Cove-Smith L, Schmitt M, Dive C, Backen A, Mescallado N, Roberts R, Mellor H, Morris D, Naish J, Jackson A, Kirk J, Hargreaves A, Galvin M, Smith S, Brocklehurst S, Price S, Betts C, Hockings P, Woodhouse N, Radford J, Linton K. 019 Chemotherapy-induced cardiotoxicity: could a translational cardiac MRI model help identify patients at risk? Heart 2017. [DOI: 10.1136/heartjnl-2017-311399.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Cooper R, Brown J, Radford J, Nelson JI. Reviews: Clinical Electroencephalography, Short-Term Visual Information Forgetting, Experiments in Psychology: A Workbook for Students, Human Visual Orientation. Perception 2016. [DOI: 10.1068/p110495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- R Cooper
- Burden Neurological Institute, Bristol BS16 1QT
| | - J Brown
- Department of Psychology, Bristol University, Bristol BS8 1HH
| | - J Radford
- Department of Psychology, North East London Polytechnic, London E15 3LJ
| | - J I Nelson
- Department of Ophthalmology PHL 811, New York University Medical Center, 550 First Avenue, New York NY 10016
| |
Collapse
|
30
|
Zinzani PL, Sasse S, Radford J, Gautam A, Bonthapally V. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. Crit Rev Oncol Hematol 2016; 104:65-70. [PMID: 27279289 DOI: 10.1016/j.critrevonc.2016.04.019] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Revised: 02/10/2016] [Accepted: 04/28/2016] [Indexed: 02/03/2023] Open
Abstract
Brentuximab vedotin was available via named patient program (NPP) to patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma in ∼60 non-US/Canadian countries, before local approval. Published results were examined recently; through systematic literature review, we identified 12 new NPP publications. Most (10/12) publications included new NPP data describing 8 unique cohorts (N=480; all R/R HL) and new participating countries. Overall response rates were 58-80%, and complete remission rates were 10-40%. With median follow-up of 9.5-26 months, median progression-free survival was 5-10.5 months and median overall survival (OS) had not been reached in most cohorts; 1- and 2-year OS was 67-76% and 58-67%, respectively. Tolerability was as expected from previous reports. Despite intrinsic bias and heterogeneous cohorts, this update supports previous findings showing comparable efficacy and tolerability of brentuximab vedotin between real-world practice and phase 2 trial results in R/R HL.
Collapse
Affiliation(s)
- P L Zinzani
- Institute of Hematology and Medical Oncology, 'L. & A. Seràgnoli', University of Bologna, Bologna, Italy.
| | - S Sasse
- University Hospital of Cologne, Cologne, Germany
| | - J Radford
- The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - A Gautam
- Global Medical Affairs, Millennium Pharmaceuticals Inc., Cambridge, MA, USA(1)
| | - V Bonthapally
- Global Oncology Pricing Market Access and Health Economics, Millennium Pharmaceuticals Inc., Cambridge, MA, USA(1)
| |
Collapse
|
31
|
O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol 2016; 27:1180. [PMID: 26945010 DOI: 10.1093/annonc/mdw095] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, Dührsen U, Ma D, Brière J, Thieblemont C, Salles G, Moskowitz CH, Glass B, Gisselbrecht C. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant 2016; 51:51-7. [PMID: 26367239 DOI: 10.1038/bmt.2015.213] [Citation(s) in RCA: 187] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Accepted: 07/31/2015] [Indexed: 01/21/2023]
Abstract
Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, the strategy is less clear in patients who require third-line treatment. Updated outcomes of 203 patients who could not proceed to scheduled ASCT in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) are herein reviewed. In the intent-to-treat analysis, overall response rate to third-line chemotherapy was 39%, with 27% CR or CR unconfirmed, and 12% PR. Among the 203 patients, 64 (31.5%) were eventually transplanted (ASCT 56, allogeneic SCT 8). Median overall survival (OS) of the entire population was 4.4 months. OS was significantly improved in patients with lower tertiary International Prognostic Index (IPI), patients responding to third-line treatment and patients transplanted with a 1-year OS of 41.6% compared with 16.3% for the not transplanted (P<0.0001). In multivariate analysis, IPI at relapse (hazard ratio (HR) 2.409) and transplantation (HR 0.375) independently predicted OS. Third-line salvage chemotherapy can lead to response followed by transplantation and long-term survival in DLBCL patients. However, improvement of salvage efficacy is an urgent need with new drugs.
Collapse
Affiliation(s)
| | - N Schmitz
- AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany
| | | | - D Gill
- Princess Alexandra Hospital, Woodville, SA, Australia
| | - D Linch
- University College London, Cancer Institute, London, UK
| | - M Trneny
- Charles Univ. General Hosp., Praha, Czech Republic
| | - N Milpied
- Hématologie Clinique et thérapie cellulaire, Hôpital Haut-Lévêque, Pessac, France
| | - J Radford
- University of Manchester, c/o Department of Medical Oncology, Christie Hospital NHS, Manchester, UK
| | - N Ketterer
- Clinique Bois-Cerf, Lausanne, Switzerland
| | | | - U Dührsen
- Universitätsklinikum Essen, KlinikfürHämatologie, Essen, Germany
| | - D Ma
- St Vincent's Hospital Sydney, Darlinghurst, NW, Australia
| | - J Brière
- Hemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France
| | - C Thieblemont
- Hemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France
| | - G Salles
- Hospices Civils de Lyon, Service d'Hématologie, Université de Lyon, Lyon, France
| | - C H Moskowitz
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - B Glass
- AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany
| | - C Gisselbrecht
- Hemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France
| |
Collapse
|
33
|
O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol 2015; 26:2505. [PMID: 26489442 DOI: 10.1093/annonc/mdv477] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- B H O'Neil
- Simon Cancer Center, Indiana University School of Medicine, Indianapolis
| | - A J Scott
- University of Colorado, Denver, Aurora
| | - W W Ma
- Roswell Park Cancer Institute, Buffalo
| | - S J Cohen
- Fox Chase Cancer Center, Philadelphia
| | | | | | | | - M A Tejani
- University of Rochester Medical Center, Rochester
| | | | | | | | - O O Olowokure
- University of Cincinnati Cancer Institute, Cincinnati
| | - J C Baranda
- University of Kansas Medical Center, Westwood
| | - M Cusnir
- Mount Sinai Medical Center, Miami Beach
| | | | - J Boles
- Rex Cancer Center UNC Healthcare, Raleigh
| | | | - M Rarick
- Kaiser Permanante Northwest, Portland
| | - D J Cohen
- NYU Clinical Cancer Center, New York
| | - J Radford
- Hendersonville Hematology and Oncology at Pardee, Hendersonville
| | | | - R Bajaj
- McLeod Regional Medical Center, Florence
| | - V Bathini
- University of Massachusetts Memorial, Worcester
| | - P Fanta
- UCSD Moores Cancer Center, La Jolla
| | - J Berlin
- Vanderbilt-Ingram Cancer Center, Nashville
| | - A J McRee
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
| | | | | | - M Maniar
- Onconova Therapeutics Inc., Newtown
| | - A Jimeno
- University of Colorado, Denver, Aurora
| | - C L Gomes
- Oncology Consortia of Criterium Inc., Saratoga Springs, USA
| | | |
Collapse
|
34
|
Zinzani P, Sasse S, Radford J, Shonukan O, Bonthapally V. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. Crit Rev Oncol Hematol 2015; 95:359-69. [DOI: 10.1016/j.critrevonc.2015.03.011] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2014] [Revised: 03/09/2015] [Accepted: 03/26/2015] [Indexed: 02/06/2023] Open
|
35
|
O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol 2015; 26:1923-1929. [PMID: 26091808 PMCID: PMC4551155 DOI: 10.1093/annonc/mdv264] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2015] [Revised: 05/13/2015] [Accepted: 05/26/2015] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) and phosphoinositide 3-kinase (PI3K), has shown efficacy in preclinical pancreatic cancer models. In this study, rigosertib was assessed in combination with gemcitabine in patients with treatment-naïve metastatic pancreatic adenocarcinoma. MATERIALS AND METHODS Patients with metastatic pancreatic adenocarcinoma were randomized in a 2:1 fashion to gemcitabine 1000 mg/m(2) weekly for 3 weeks of a 4-week cycle plus rigosertib 1800 mg/m(2) via 2-h continuous IV infusions given twice weekly for 3 weeks of a 4-week cycle (RIG + GEM) versus gemcitabine 1000 mg/m(2) weekly for 3 weeks in a 4-week cycle (GEM). RESULTS A total of 160 patients were enrolled globally and randomly assigned to RIG + GEM (106 patients) or GEM (54). The most common grade 3 or higher adverse events were neutropenia (8% in the RIG + GEM group versus 6% in the GEM group), hyponatremia (17% versus 4%), and anemia (8% versus 4%). The median overall survival was 6.1 months for RIG + GEM versus 6.4 months for GEM [hazard ratio (HR), 1.24; 95% confidence interval (CI) 0.85-1.81]. The median progression-free survival was 3.4 months for both groups (HR = 0.96; 95% CI 0.68-1.36). The partial response rate was 19% versus 13% for RIG + GEM versus GEM, respectively. Of 64 tumor samples sent for molecular analysis, 47 were adequate for multiplex genetic testing and 41 were positive for mutations. The majority of cases had KRAS gene mutations (40 cases). Other mutations detected included TP53 (13 cases) and PIK3CA (1 case). No correlation between mutational status and efficacy was detected. CONCLUSIONS The combination of RIG + GEM failed to demonstrate an improvement in survival or response compared with GEM in patients with metastatic pancreatic adenocarcinoma. Rigosertib showed a similar safety profile to that seen in previous trials using the IV formulation.
Collapse
Affiliation(s)
- B H O'Neil
- Simon Cancer Center, Indiana University School of Medicine, Indianapolis
| | - A J Scott
- University of Colorado, Denver, Aurora
| | - W W Ma
- Roswell Park Cancer Institute, Buffalo
| | - S J Cohen
- Fox Chase Cancer Center, Philadelphia
| | | | | | - M A Tejani
- University of Rochester Medical Center, Rochester
| | | | | | | | - O O Olowokure
- University of Cincinnati Cancer Institute, Cincinnati
| | - J C Baranda
- University of Kansas Medical Center, Westwood
| | - M Cusnir
- Mount Sinai Medical Center, Miami Beach
| | | | - J Boles
- Rex Cancer Center UNC Healthcare, Raleigh
| | | | - M Rarick
- Kaiser Permanante Northwest, Portland
| | - D J Cohen
- NYU Clinical Cancer Center, New York
| | - J Radford
- Hendersonville Hematology and Oncology at Pardee, Hendersonville
| | | | - R Bajaj
- McLeod Regional Medical Center, Florence
| | - V Bathini
- University of Massachusetts Memorial, Worcester
| | - P Fanta
- UCSD Moores Cancer Center, La Jolla
| | - J Berlin
- Vanderbilt-Ingram Cancer Center, Nashville
| | - A J McRee
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
| | | | | | - M Maniar
- Onconova Therapeutics Inc., Newtown
| | - A Jimeno
- University of Colorado, Denver, Aurora
| | - C L Gomes
- Oncology Consortia of Criterium Inc., Saratoga Springs, USA
| | | |
Collapse
|
36
|
Radford J, Howell S, Spoor W, O'Hara C, Vaughan K, Goode V, Hartley R, Davies S, Cowan R, Swerdlow A. The Breast Screening after Radiotherapy Dataset (BARD): a National Initiative to Optimise Screening for Breast cancer in Female Hodgkin Lymphoma Survivors in England. Klin Padiatr 2014. [DOI: 10.1055/s-0034-1371159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
37
|
Govi S, Christie D, Messina C, Bruno Ventre M, Gracia Medina E, Porter D, Radford J, Seog Heo D, Park Y, Martinelli G, Taylor E, Lucraft H, Ballova V, Zucca E, Gospodarowicz M, Ferreri A. The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone. Ann Oncol 2014; 25:176-81. [DOI: 10.1093/annonc/mdt482] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
38
|
Affiliation(s)
- J.W. Burdick
- a Department of Mechanical Engineering, Mail Code 104-44, California Institute of Technology, Pasadena, CA 91125, USA
| | - J. Radford
- b Department of Mechanical Engineering, Mail Code 104-44, California Institute of Technology, Pasadena, CA 91125, USA
| | - G.S. Chirikjian
- c Department of Mechanical Engineering, 124 Latrobe Hall, Johns Hopkins University, Baltimore, MD 21218, USA
| |
Collapse
|
39
|
Laverty H, Benson C, Cartwright E, Cross M, Garland C, Hammond T, Holloway C, McMahon N, Milligan J, Park B, Pirmohamed M, Pollard C, Radford J, Roome N, Sager P, Singh S, Suter T, Suter W, Trafford A, Volders P, Wallis R, Weaver R, York M, Valentin J. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol 2011; 163:675-93. [PMID: 21306581 DOI: 10.1111/j.1476-5381.2011.01255.x] [Citation(s) in RCA: 246] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Given that cardiovascular safety liabilities remain a major cause of drug attrition during preclinical and clinical development, adverse drug reactions, and post-approval withdrawal of medicines, the Medical Research Council Centre for Drug Safety Science hosted a workshop to discuss current challenges in determining, understanding and addressing 'Cardiovascular Toxicity of Medicines'. This article summarizes the key discussions from the workshop that aimed to address three major questions: (i) what are the key cardiovascular safety liabilities in drug discovery, drug development and clinical practice? (ii) how good are preclinical and clinical strategies for detecting cardiovascular liabilities? and (iii) do we have a mechanistic understanding of these liabilities? It was concluded that in order to understand, address and ultimately reduce cardiovascular safety liabilities of new therapeutic agents there is an urgent need to: • Fully characterize the incidence, prevalence and impact of drug-induced cardiovascular issues at all stages of the drug development process. • Ascertain the predictive value of existing non-clinical models and assays towards the clinical outcome. • Understand the mechanistic basis of cardiovascular liabilities; by addressing areas where it is currently not possible to predict clinical outcome based on preclinical safety data. • Provide scientists in all disciplines with additional skills to enable them to better integrate preclinical and clinical data and to better understand the biological and clinical significance of observed changes. • Develop more appropriate, highly relevant and predictive tools and assays to identify and wherever feasible to eliminate cardiovascular safety liabilities from molecules and wherever appropriate to develop clinically relevant and reliable safety biomarkers.
Collapse
Affiliation(s)
- Hg Laverty
- MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The University of Liverpool, Merseyside, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Barrington SF, MacKewn JE, Schleyer P, Marsden PK, Mikhaeel NG, Qian W, Mouncey P, Patrick P, Popova B, Johnson P, Radford J, O'Doherty MJ. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol 2010; 22:739-745. [PMID: 20813876 DOI: 10.1093/annonc/mdq428] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND Multicentre trials are required to determine how [fluorine-18]-2-fluoro-2-deoxy-D-glucose-positron emission tomography imaging can guide cancer treatment. Consistency in quality control (QC), scan acquisition and reporting is mandatory for high-quality results, which are comparable across sites. METHODS A national positron emission tomography (PET) clinical trials network (CTN) has been set up with a 'core laboratory' to coordinate QC and interpret scans. The CTN is involved in trials in Hodgkin's lymphoma [Randomised Phase III trial to determine the role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease (RAPID) and Randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin lymphoma (RATHL)] and diffuse large B-cell lymphoma [Blinded evaluation of prognostic value of FDG-PET after 2 cycles of chemotherapy in diffuse large B-cell Non-Hodgkins Lymphoma, a sub-study of the R-CHOP-21 vs R-CHOP-14 trial (R-CHOP PET substudy)]. Approval to join requires scanner validation and agreement to follow a standard QC protocol. Scans are transferred to the core laboratory and reported centrally according to predetermined criteria. RESULTS The qualification procedure was carried out on 15 scanners. All scanners were able to demonstrate the necessary quantitative accuracy, and following modification of image reconstruction where necessary, scanners demonstrated comparable recovery coefficients (RCs) indicating similar performance. The average RC (±1 standard deviation) was 0.56 ± 0.095 for the 13-mm sphere. Reports from 444 of 473 (94%) patients in RAPID and 67 of 73 (92%) patients in RATHL were available for randomisation of therapy. CONCLUSIONS The CTN has enabled consistent quality assured PET results to be obtained from multiple centres in time for clinical decision making. The results of trials will be significantly strengthened by this system.
Collapse
Affiliation(s)
- S F Barrington
- Division of Imaging Sciences, PET Imaging Centre at St Thomas', Kings College London, London.
| | - J E MacKewn
- Division of Imaging Sciences, PET Imaging Centre at St Thomas', Kings College London, London
| | - P Schleyer
- Division of Imaging Sciences, PET Imaging Centre at St Thomas', Kings College London, London
| | - P K Marsden
- Division of Imaging Sciences, PET Imaging Centre at St Thomas', Kings College London, London
| | - N G Mikhaeel
- Department of Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust, London
| | - W Qian
- MRC Clinical Trials Unit, London
| | - P Mouncey
- Cancer Research UK and UCL Clinical Trials Centre, London
| | - P Patrick
- Cancer Research UK and UCL Clinical Trials Centre, London
| | - B Popova
- Cancer Research UK and UCL Clinical Trials Centre, London
| | - P Johnson
- Cancer Research UK Clinical Centre, Southampton
| | - J Radford
- The Christie NHS Foundation Trust, Manchester; University of Manchester, Manchester, UK
| | - M J O'Doherty
- Division of Imaging Sciences, PET Imaging Centre at St Thomas', Kings College London, London
| |
Collapse
|
41
|
Grant A, Trompf K, Seung D, Nivison-Smith L, Bowcock H, Kresse H, Holmes S, Radford J, Morrow P. Sub-cellular damage by copper in the cnidarian Zoanthus robustus. Comp Biochem Physiol C Toxicol Pharmacol 2010; 152:256-62. [PMID: 20462520 DOI: 10.1016/j.cbpc.2010.04.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2010] [Revised: 04/30/2010] [Accepted: 04/30/2010] [Indexed: 11/26/2022]
Abstract
Sessile organisms may experience chronic exposure to copper that is released into the marine environment from antifoulants and stormwater runoff. We have identified the site of damage caused by copper to the symbiotic cnidarian, Zoanthus robustus (Anthozoa, Hexacorallia). External changes to the zoanthids were apparent when compared with controls. The normally flexible bodies contracted and became rigid. Histological examination of the zoanthid tissue revealed that copper had caused sub-cellular changes to proteins within the extracellular matrix (ECM) of the tubular body. Collagen in the ECM and the internal septa increased in thickness to five and seven times that of controls respectively. The epithelium, which stained for elastin, was also twice as thick and tough to cut, but exposure to copper did not change the total amount of desmosine which is found only in elastin. We conclude that copper stimulated collagen synthesis in the ECM and also caused cross-linking of existing proteins. However, there was no expulsion of the symbiotic algae (Symbiodinium sp.) and no effect on algal pigments or respiration (44, 66 and 110 microg Cu L(-1)). A decrease in net photosynthesis was observed only at the highest copper concentration (156 microg Cu L(-1)). These results show that cnidarians may be more susceptible to damage by copper than their symbiotic algae.
Collapse
Affiliation(s)
- A Grant
- School of Biological Sciences, Department of Pathology, University of Sydney, 2006, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Cunningham D, Smith P, Mouncey P, Qian W, Pocock C, Ardeshna KM, Radford J, Davies J, McMillan A, Linch D. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8506] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8506 Background: The addition of rituximab to standard therapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP21) has resulted in improved survival outcomes in the treatment of diffuse large B-cell non-Hodgkin's lymphoma (DLBC NHL). In addition, the administration of CHOP as a 14 day cycle (CHOP14) has shown benefit over standard CHOP21 chemotherapy. This randomised study was designed to evaluate the toxicity and survival outcomes achieved with the addition of rituximab to CHOP14 (R-CHOP14), as compared to standard therapy (R-CHOP21) in newly diagnosed DLBC NHL. Methods: Patients were randomised to receive either eight cycles of standard R-CHOP21 or six cycles of R-CHOP14 (+ G-CSF) with two additional cycles of single agent rituximab. Randomisation was stratified by age (≤60 vs >60), WHO performance status (0–1 vs 2) and LDH level (normal vs raised). The primary endpoint is overall survival. The study was powered to detect an improvement in 2-year survival in the R-CHOP14 arm of 8% (70% to 78%) with 5% significance and 90% power (2-sided). Results: Recruitment is complete with 1080 patients randomised. Patient characteristics in the R-CHOP21 and R-CHOP14 arms are; IPI score of ≥4 17%:15%, stage III/IV disease 63%:62%, B symptoms 44%:47%, bulk disease 51%:48%. Median age is 61 years in both arms. 82% of patients in the R-CHOP21 arm completed study therapy as compared to 89% in the R-CHOP14 arm. Reported grade III/IV toxicities in the R-CHOP21 and R-CHOP14 arms are; neutropenia 57%:31%, thrombocytopenia 5%:9%, Infection 22%:17%, cardiac 1%:2%, nausea & vomiting 8%:8%, mucositis 2%:3%. The radiological complete response rate (CR/CRu) is 47% in both treatment arms. With a median follow-up 14 months 805 patients remain alive. Conclusions: Results indicate that R-CHOP14 can be delivered as effectively as R-CHOP21 with comparable levels of acute toxicity. Final analysis will be performed when 330 deaths have occurred. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Cunningham
- The Royal Marsden Hospital, London and Surrey, United Kingdom; Cancer Research UK, London, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Kent and Canterbury Hospital, Canterbury, United Kingdom; Mount Vernon Cancer Centre, Northwood, United Kingdom; Christie Hospital, Manchester, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; University College Hospital, London, United Kingdom
| | - P. Smith
- The Royal Marsden Hospital, London and Surrey, United Kingdom; Cancer Research UK, London, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Kent and Canterbury Hospital, Canterbury, United Kingdom; Mount Vernon Cancer Centre, Northwood, United Kingdom; Christie Hospital, Manchester, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; University College Hospital, London, United Kingdom
| | - P. Mouncey
- The Royal Marsden Hospital, London and Surrey, United Kingdom; Cancer Research UK, London, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Kent and Canterbury Hospital, Canterbury, United Kingdom; Mount Vernon Cancer Centre, Northwood, United Kingdom; Christie Hospital, Manchester, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; University College Hospital, London, United Kingdom
| | - W. Qian
- The Royal Marsden Hospital, London and Surrey, United Kingdom; Cancer Research UK, London, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Kent and Canterbury Hospital, Canterbury, United Kingdom; Mount Vernon Cancer Centre, Northwood, United Kingdom; Christie Hospital, Manchester, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; University College Hospital, London, United Kingdom
| | - C. Pocock
- The Royal Marsden Hospital, London and Surrey, United Kingdom; Cancer Research UK, London, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Kent and Canterbury Hospital, Canterbury, United Kingdom; Mount Vernon Cancer Centre, Northwood, United Kingdom; Christie Hospital, Manchester, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; University College Hospital, London, United Kingdom
| | - K. M. Ardeshna
- The Royal Marsden Hospital, London and Surrey, United Kingdom; Cancer Research UK, London, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Kent and Canterbury Hospital, Canterbury, United Kingdom; Mount Vernon Cancer Centre, Northwood, United Kingdom; Christie Hospital, Manchester, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; University College Hospital, London, United Kingdom
| | - J. Radford
- The Royal Marsden Hospital, London and Surrey, United Kingdom; Cancer Research UK, London, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Kent and Canterbury Hospital, Canterbury, United Kingdom; Mount Vernon Cancer Centre, Northwood, United Kingdom; Christie Hospital, Manchester, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; University College Hospital, London, United Kingdom
| | - J. Davies
- The Royal Marsden Hospital, London and Surrey, United Kingdom; Cancer Research UK, London, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Kent and Canterbury Hospital, Canterbury, United Kingdom; Mount Vernon Cancer Centre, Northwood, United Kingdom; Christie Hospital, Manchester, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; University College Hospital, London, United Kingdom
| | - A. McMillan
- The Royal Marsden Hospital, London and Surrey, United Kingdom; Cancer Research UK, London, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Kent and Canterbury Hospital, Canterbury, United Kingdom; Mount Vernon Cancer Centre, Northwood, United Kingdom; Christie Hospital, Manchester, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; University College Hospital, London, United Kingdom
| | - D. Linch
- The Royal Marsden Hospital, London and Surrey, United Kingdom; Cancer Research UK, London, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Kent and Canterbury Hospital, Canterbury, United Kingdom; Mount Vernon Cancer Centre, Northwood, United Kingdom; Christie Hospital, Manchester, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; University College Hospital, London, United Kingdom
| |
Collapse
|
43
|
Chanudet E, Ye H, Ferry J, Bacon CM, Adam P, Müller-Hermelink HK, Radford J, Pileri SA, Ichimura K, Collins VP, Hamoudi RA, Nicholson AG, Wotherspoon AC, Isaacson PG, Du MQ. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J Pathol 2009; 217:420-30. [PMID: 19006194 DOI: 10.1002/path.2466] [Citation(s) in RCA: 105] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The genetic basis of MALT lymphoma is largely unknown. Characteristic chromosomal translocations are frequently associated with gastric and pulmonary cases, but are rare at other sites. We compared the genetic profiles of 33 ocular adnexal and 25 pulmonary MALT lymphomas by 1 Mb array-comparative genomic hybridization (CGH) and revealed recurrent 6q23 losses and 6p21.2-6p22.1 gains exclusive to ocular cases. High-resolution chromosome 6 tile-path array-CGH identified NF-kappaB inhibitor A20 as the target of 6q23.3 deletion and TNFA/B/C locus as a putative target of 6p21.2-22.1 gain. Interphase fluorescence in situ hybridization showed that A20 deletion occurred in MALT lymphoma of the ocular adnexa (8/42=19%), salivary gland (2/24=8%), thyroid (1/9=11%) and liver (1/2), but not in the lung (26), stomach (45) and skin (13). Homozygous deletion was observed in three cases. A20 deletion and TNFA/B/C gain were significantly associated (p<0.001) and exclusively found in cases without characteristic translocation. In ocular cases, A20 deletion was associated with concurrent involvement of different adnexal tissues or extraocular sites at diagnosis (p=0.007), a higher proportion of relapse (67% versus 37%) and a shorter relapse-free survival (p=0.033). A20 deletion and gain at TNFA/B/C locus may thus play an important role in the development of translocation-negative MALT lymphoma.
Collapse
Affiliation(s)
- E Chanudet
- Division of Molecular Histopathology, Department of Pathology, University of Cambridge, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
|
45
|
Warraich ST, Allbutt HN, Billing R, Radford J, Coster MJ, Kassiou M, Henderson JM. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model. Brain Res Bull 2008; 78:85-90. [PMID: 18822357 DOI: 10.1016/j.brainresbull.2008.08.023] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The degeneration of the dopaminergic nigrostriatal pathway in Parkinson's disease (PD) is associated with altered transmission at striatal NMDA receptors containing NR2B subunits. We investigated a potential novel therapeutic compound, 4-trifluoromethoxy-N-(2-trifluoromethyl-benzyl)-benzamidine (BZAD-01), a selective NMDA NR1A/2B receptor antagonist for PD and compared it with levodopa, the standard treatment for PD. This study also evaluated whether combining levodopa and BZAD-01 gave better improvements of parkinsonian symptoms. Parkinsonism was induced by microinjection of the toxin, 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle (MFB) of 40 Sprague-Dawley rats. Parkinsonism and the efficacy of drugs were assessed using a battery of behavioural tests including balance beam, apomorphine-induced rotation, body axis bias or "curling", head position bias and disengage sensorimotor latency test. Immunohistochemistry was performed on post-mortem tissue to estimate the loss of dopaminergic neurons. The main effects were that BZAD-01 co-administration prevented chronic levodopa-induced potentiation of apomorphine rotation. However levodopa-treated rats were slower than either controls or BZAD-01-treated rats in the locomotor test. The improvement in the apomorphine rotation test suggests that BZAD-01 may be a useful adjunct to levodopa monotherapy.
Collapse
Affiliation(s)
- S T Warraich
- Department of Pharmacology, Bosch Institute and School of Medical Sciences, University of Sydney, NSW 2006, Australia
| | | | | | | | | | | | | |
Collapse
|
46
|
Ferreri AJM, Dolcetti R, Du MQ, Doglioni C, Resti AG, Politi LS, De Conciliis C, Radford J, Bertoni F, Zucca E, Cavalli F, Ponzoni M. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Ann Oncol 2007; 19:835-46. [PMID: 17986622 DOI: 10.1093/annonc/mdm513] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Non-Hodgkin's lymphomas constitute one half of malignancies arising in the orbit and the ocular adnexae. Mucosa-associated lymphoid tissue (MALT)-type lymphoma is the most common histological category in this anatomic region. The incidence of ocular adnexal lymphoma of mucosa-associated lymphoid tissue-type (OAML) is increasing and recent studies offered new relevant insights in molecular, pathogenetic and therapeutic issues on these neoplasms. A pathogenetic model of antigen-driven lymphoproliferation similar to that reported for Helicobacter pylori-related gastric MALT lymphomas has been hypothesized for OAML. This notion is supported by the association between OAML and Chlamydophila psittaci infection, an association that is of likely pathogenetic relevance and may influence both the biological behavior and the therapeutic management of these neoplasms. However, this association displays evident geographical variability indicating that other etiopathogenic agents could be involved. These recent acquisitions coupled with the occurrence of chromosomal translocations and other genetic alterations, as well as additional risk factors like autoimmune disorders have contributed to render OAML an exciting challenge for a broad group of physicians and scientists. OAML is an indolent and rarely lethal malignancy that, in selected patients, can be managed with observation alone. Lymphomatous lesions are frequently responsible for symptoms affecting patient's quality of life, requiring, therefore, immediate treatment. Several therapeutic strategies are available, often associated with relevant side-effects. However, the therapeutic choice in OAML is not supported by consolidated evidence due to the lack of prospective trials. In this review, we analyze the most relevant biological, molecular, pathological and clinical features of OAML and propose some therapeutic guidelines for patients affected by this malignancy.
Collapse
Affiliation(s)
- A J M Ferreri
- Unit of Lymphoid Malignancies, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, Roos D, Lennard A, Devizzi L, Crabb S, Hossfeld D, Pratt G, Dell'Olio M, Choo SP, Bociek RG, Radford J, Lade S, Gianni AM, Zucca E, Cavalli F, Seymour JF. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2007; 19:233-41. [PMID: 17932394 DOI: 10.1093/annonc/mdm471] [Citation(s) in RCA: 143] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Primary diffuse large B-cell lymphoma (DLBCL) of breast is rare. We aimed to define clinical features, prognostic factors, patterns of failure, and treatment outcomes. PATIENTS AND METHODS A retrospective international study of 204 eligible patients presenting to the International Extranodal Lymphoma Study Group-affiliated institutions from 1980 to 2003. RESULTS Median age was 64 years, with 95% of patients presenting with unilateral disease. Median overall survival (OS) was 8.0 years, and median progression-free survival 5.5 years. In multifactor analysis, favourable International Prognostic Index score, anthracycline-containing chemotherapy, and radiotherapy (RT) were significantly associated with longer OS (each P < or = 0.03). There was no benefit from mastectomy, as opposed to biopsy or lumpectomy only. At a median follow-up time of 5.5 years, 37% of patients had progressed--16% in the same or contralateral breast, 5% in the central nervous system, and 14% in other extranodal sites. CONCLUSIONS The combination of limited surgery, anthracycline-containing chemotherapy, and involved-field RT produced the best outcome in the pre-rituximab era. A prospective trial on the basis of these results should be pursued to confirm these observations and to determine whether the impact of rituximab on the patterns of relapse and outcome parallels that of DLBCL presenting at other sites.
Collapse
Affiliation(s)
- G Ryan
- Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, Biti G, Bogatyreva T, Bonadonna G, Brillant C, Cavalieri E, Diehl V, Eghbali H, Fermé C, Henry-Amar M, Hoppe R, Howard S, Meyer R, Niedzwiecki D, Pavlovsky S, Radford J, Raemaekers J, Ryder D, Schiller P, Shakhtarina S, Valagussa P, Wilimas J, Yahalom J. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006; 17:1749-60. [PMID: 16984979 DOI: 10.1093/annonc/mdl302] [Citation(s) in RCA: 151] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Despite several investigations, second malignancy risks (SMR) following radiotherapy alone (RT), chemotherapy alone (CT) and combined chemoradiotherapy (CRT) for Hodgkin's lymphoma (HL) remain controversial. PATIENTS AND METHODS We sought individual patient data from randomised trials comparing RT versus CRT, CT versus CRT, RT versus CT or involved-field (IF) versus extended-field (EF) RT for untreated HL. Overall SMR (including effects of salvage treatment) were compared using Peto's method. RESULTS Data for between 53% and 69% of patients were obtained for the four comparisons. (i) RT versus CRT (15 trials, 3343 patients): SMR were lower with CRT than with RT as initial treatment (odds ratio (OR) = 0.78, 95% confidence interval (CI) = 0.62-0.98 and P = 0.03). (ii) CT versus CRT (16 trials, 2861 patients): SMR were marginally higher with CRT than with CT as initial treatment (OR = 1.38, CI 1.00-1.89 and P = 0.05). (iii) IF-RT versus EF-RT (19 trials, 3221 patients): no significant difference in SMR (P = 0.28) although more breast cancers occurred with EF-RT (P = 0.04 and OR = 3.25). CONCLUSIONS Administration of CT in addition to RT as initial therapy for HL decreases overall SMR by reducing relapse and need for salvage therapy. Administration of RT additional to CT marginally increases overall SMR in advanced stages. Breast cancer risk (but not SMR in general) was substantially higher after EF-RT. Caution is needed in applying these findings to current therapies.
Collapse
Affiliation(s)
- J Franklin
- German Hodgkin Study Group, University of Cologne, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Strong M, Maheswaran R, Radford J. Reply. J Public Health (Oxf) 2006. [DOI: 10.1093/pubmed/fdl021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Walewski J, Mead G, Jack A, Barrans S, Radford J, Clawson S, Stenning S, Qian W. Defining Burkitt’s lymphoma (BL) with cytogenetics: LY10, a prospective clinicopathological study of dose-reduced (dr) CODOX-M/IVAC in patients with 100% Ki-67 staining B-cell non-Hodgkin’s lymphoma (NHL). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7557 Background: Previous studies suggest that CODOX-M/IVAC is effective therapy for BL (Ann Onc 2002 13:1264–74), however the diagnosis of BL in this and other studies was not based on modern immunochemistry and cytogenetics and is unreliable. To re-evaluate this question we prospectively studied a population of patients (pts) with aggressive B-cell lymphoma (100% Ki-67+) uniformly treated with dr CODOX-M/IVAC. Methods: Pts ≤65 years with B-cell lymphomas showing 100% Ki-67, considered fit for chemotherapy, received either dr CODOX-M x 3 or dr CODOX-M/IVAC x 4 according to a modified international prognostic index (IPI). Chemotherapy was modified by methotrexate dose reduction to 3g/m2. Pts >65 years had further dose reductions; unfit pts were studied pathologically only. Tumours were characterised using both an extended panel of antibodies and interphase FISH on paraffin sections for the presence of the C-MYC and BCL-2 rearrangements. Results: Of 126 pts reviewed centrally, 5 were ineligible; 53 were diagnosed as BL, each based on the combination of the presence of re-arrangement of C-MYC as a sole abnormality, germinal centre phenotype and p53 abnormality. The final 68 cases were highly heterogenous with respect to tumour phenotype and cytogenetics and were diagnosed as diffuse large B-cell lymphoma (DLBCL). Median age (all pts) was 44 years (range 17–83), with 23 aged >65. Compared with the DLBCL pts, BL pts were significantly younger (mean 38yrs vs 53 yrs, p < 0.001), had more marrow involvement (45% vs 24%, p = 0.02) and male predominance (83% vs 65%, p = 0.03). Of 104 pts entered into the clincal study, 32 pts (10 BL, 22 DLBCL, IPI 0,1) received dr CODOX-M x 3 and 72 (39 BL, 33 DLBCL, IPI >1) received dr CODOX-M/IVAC x 4. With median follow-up of 15 months (range 1 to 37), 1 year progression-free survival was 58%, 95% CI 48%-68% (54% BL vs 62% DLBCL) and 1 year survival 61% 95% CI 51%-71% (55% BL vs 66% DLBC). Conclusions: The study shows Ki67 is not an accurate approach to the diagnosis of BL and the use of immunocytochemistry and FISH is essential. BL and DLBCL as defined differ markedly clinically. Preliminary data suggest that dr CODOX-M/IVAC has similar activity in both histologies. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Walewski
- Southampton General Hosp, Southampton, United Kingdom; HMDS, Leeds General Infirmary, United Kingdom; MSCM Cancer Centre, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom
| | - G. Mead
- Southampton General Hosp, Southampton, United Kingdom; HMDS, Leeds General Infirmary, United Kingdom; MSCM Cancer Centre, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom
| | - A. Jack
- Southampton General Hosp, Southampton, United Kingdom; HMDS, Leeds General Infirmary, United Kingdom; MSCM Cancer Centre, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom
| | - S. Barrans
- Southampton General Hosp, Southampton, United Kingdom; HMDS, Leeds General Infirmary, United Kingdom; MSCM Cancer Centre, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom
| | - J. Radford
- Southampton General Hosp, Southampton, United Kingdom; HMDS, Leeds General Infirmary, United Kingdom; MSCM Cancer Centre, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom
| | - S. Clawson
- Southampton General Hosp, Southampton, United Kingdom; HMDS, Leeds General Infirmary, United Kingdom; MSCM Cancer Centre, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom
| | - S. Stenning
- Southampton General Hosp, Southampton, United Kingdom; HMDS, Leeds General Infirmary, United Kingdom; MSCM Cancer Centre, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom
| | - W. Qian
- Southampton General Hosp, Southampton, United Kingdom; HMDS, Leeds General Infirmary, United Kingdom; MSCM Cancer Centre, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom
| |
Collapse
|